{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=68", "query": { "condition": "Carcinoma, Bronchogenic", "page": 68 }, "page_size": 10 }, "pagination": { "page": 68, "page_size": 10, "total_count": 3597, "total_pages": 360, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=69&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=67&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T06:55:09.442Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03916627", "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "cemiplimab", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" }, { "name": "fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2019-07-23", "completion_date": "2030-05-14", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03916627" }, { "nct_id": "NCT00097227", "title": "Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2004-11", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2010-04-09", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 20, "location_summary": "Los Angeles, California • Santa Monica, California • Newark, Delaware + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097227" }, { "nct_id": "NCT01387269", "title": "Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cachexia", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Anamorelin HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Therapeutics (U.S.), Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 484, "start_date": "2011-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-10-27", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 12, "location_summary": "Fullerton, California • Glendale, California • La Jolla, California + 9 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387269" }, { "nct_id": "NCT03741829", "title": "TS Overexpression in SCLC: Mechanism and Therapeutic Targeting", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-06-14", "completion_date": "2020-01-03", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03741829" }, { "nct_id": "NCT05614102", "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BAY2965501", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum-based Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2022-11-04", "completion_date": "2027-04-14", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 3, "location_summary": "Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614102" }, { "nct_id": "NCT01344824", "title": "Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2010-03", "completion_date": "2016-07-20", "has_results": true, "last_update_posted_date": "2017-10-30", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 4, "location_summary": "Asheville, North Carolina • Chapel Hill, North Carolina • New Bern, North Carolina + 1 more", "locations": [ { "city": "Asheville", "state": "North Carolina" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "New Bern", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01344824" }, { "nct_id": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INC280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2012-02-29", "completion_date": "2017-07-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324479" }, { "nct_id": "NCT04676386", "title": "Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NSCLC Stage IV", "NSCLC, Stage IIIC" ], "interventions": [ { "name": "Primary Immune Response (PIR) test by Biodesix, Inc.", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Addario Lung Cancer Medical Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 29, "start_date": "2021-02-01", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 2, "location_summary": "San Carlos, California • Chicago, Illinois", "locations": [ { "city": "San Carlos", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676386" }, { "nct_id": "NCT02521051", "title": "Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-09-28", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02521051" }, { "nct_id": "NCT00033553", "title": "Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2002-03", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-10-30T06:55:09.442Z", "location_count": 74, "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033553" } ] }